Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

Protocol: L002G
______________________________________________________________________________

| 784 |L03AB07| INTERFERONUM BETA 1a**** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L03AB07 INTERFERONUM BETA 1a SOL. INJ. 22 µg/0,5 ml

REBIF 22 µg 22 µg/0,5 ml SERONO EUROPE LTD.
L03AB07 INTERFERONUM BETA 1a PULB. + SOLV. PT. SOL. 30 µg (6 mil. UI)

INJ.

AVONEX 30 µg BIO-SET 30 µg (6 mil. UI) BIOGEN IDEC LIMITED
L03AB07 INTERFERONUM BETA 1a SOL. INJ. 44 µg

REBIF 44 µg 44 µg SERONO EUROPE LTD.

________________________________________________________________________________
______________________________________________________________________________

| 785 |L03AB08| INTERFERONUM BETA 1B**** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L03AB08 INTERFERONUM BETA 1B PULB. + SOLV. PT. SOL. 250 µg/ml

INJ.

BETAFERON 250 µg/ml 250 µg/ml BAYER SCHERING AG

________________________________________________________________________________
______________________________________________________________________________

| 786 |L03AX13| GLATIRAMER ACETAT**** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L03AX13 GLATIRAMER ACETAT SOL. INJ. 20 mg/ml

COPAXONE 20 mg/ml TEVA PHARMACEUTICALS

S.R.L.

________________________________________________________________________________
______________________________________________________________________________

| 787 |L04AA23| NATALIZUMABUM**** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AA23 NATALIZUMABUM CONC. PT. SOL. PERF. 20 mg/ml

TYSABRI 300 mg 20 mg/ml ELAN PHARMA INTERNATIONAL

LTD
A fost raportat la acest medicament leucoencefalopatie multifocală progresivă.

________________________________________________________________________________
______________________________________________________________________________

| 788 |L04AX01| AZATHIOPRINUM* | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AX01 AZATHIOPRINUM COMPR. FILM. 50 mg

IMURAN(R) 50 mg THE WELLCOME FOUNDATION

LTD.

________________________________________________________________________________
SUBLISTA C2 - P5: PROGRAMUL NAŢIONAL DE DIABET ZAHARAT.